Description
A selective, orally bioavailable inhibitor of Akt (IC50s = 180, 328, and 38 nM for Akt1, Akt2, and Akt3, respectively); preferentially inhibits the proliferation of human cancer cells lines with Akt pathway activation via PI3K/PTEN mutation or loss
Formal name: N-[(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl]-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-furancarboxamide
Synonyms: GSK2141795|GSK795
Molecular weight: 429.2
CAS: 1047634-65-0
Purity: ≥98%
Formulation: A crystalline solid
Product Type|Biochemicals|Kinase Inhibitors|Activin-like Kinases (ALKs)||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cancer|Cell Cycle||Research Area|Cancer|Cell Signaling|PI3K/Akt/mTOR Signaling
